All of these markers were normalized after anti-TLR4 antibody treatment, but neither blood pressure nor left ventricular hypertrophy was modulated, indicating that inflammation through TLR4 signaling contributed only to pro-fibrotic phenotype. Here, TLR4 is linked to left ventricular hypertrophy.